Allogene Therapeutics Inc (NASDAQ:ALLO) – Research analysts at William Blair issued their Q1 2020 earnings estimates for shares of Allogene Therapeutics in a report released on Monday, April 15th, Zacks Investment Research reports. William Blair analyst R. Prasad anticipates that the company will post earnings per share of ($0.66) for the quarter. William Blair has a “Buy” rating on the stock. William Blair also issued estimates for Allogene Therapeutics’ Q2 2020 earnings at ($0.68) EPS, Q3 2020 earnings at ($0.69) EPS and Q4 2020 earnings at ($0.74) EPS.
Allogene Therapeutics (NASDAQ:ALLO) last released its earnings results on Tuesday, May 7th. The company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.08.
Shares of NASDAQ ALLO traded up $0.29 during trading hours on Wednesday, hitting $30.31. 419,948 shares of the company traded hands, compared to its average volume of 392,861. The company has a market cap of $3.65 billion and a P/E ratio of -4.61. Allogene Therapeutics has a 12 month low of $21.67 and a 12 month high of $35.55.
Institutional investors have recently made changes to their positions in the business. Barclays PLC bought a new position in Allogene Therapeutics in the 4th quarter valued at $27,000. Legal & General Group Plc bought a new position in Allogene Therapeutics in the 4th quarter valued at $89,000. Partner Investment Management L.P. purchased a new stake in shares of Allogene Therapeutics in the 4th quarter worth $135,000. NumerixS Investment Technologies Inc purchased a new stake in shares of Allogene Therapeutics in the 1st quarter worth $136,000. Finally, Citigroup Inc. purchased a new stake in shares of Allogene Therapeutics in the 4th quarter worth $152,000. 51.59% of the stock is currently owned by institutional investors.
About Allogene Therapeutics
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
Featured Story: What does the Dow Jones Industrial Average (DJIA) measure?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.